Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.

NCT00249119 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.

NCT NCT00249119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00249119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.
Lead sponsor
Janssen, LP
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
December 31, 1991
Enrollment
1,579 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorder, schizophrenia